[HTML][HTML] Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia
Background In a multinational, phase 3, head-to-head trial, ibrutinib, a Bruton's tyrosine
kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater …
kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater …
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
JR Brown, B Eichhorst, P Hillmen… - … England Journal of …, 2023 - publicum.umed.lodz.pl
Background: In a multinational, phase 3, head-to-head trial, ibrutinib, a Bruton's tyrosine
kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater …
kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater …
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
J Brown, B Eichhorst, P Hillmen, W Jurczak… - 2023 - med.muni.cz
BACKGROUND In a multinational, phase 3, head-to-head trial, ibrutinib, a Bruton's tyrosine
kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater …
kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater …
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
JR Brown, B Eichhorst, P Hillmen… - The New England …, 2023 - pubmed.ncbi.nlm.nih.gov
Background In a multinational, phase 3, head-to-head trial, ibrutinib, a Bruton's tyrosine
kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater …
kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater …
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
JR Brown, B Eichhorst, P Hillmen… - The New England …, 2022 - europepmc.org
Background In a multinational, phase 3, head-to-head trial, ibrutinib, a Bruton's tyrosine
kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater …
kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater …
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
JR Brown, B Eichhorst, P Hillmen… - New England …, 2023 - mdanderson.elsevierpure.com
Background: In a multinational, phase 3, head-to-head trial, ibrutinib, a Bruton's tyrosine
kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater …
kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater …
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
J Brown, B Eichhorst, P Hillmen, W Jurczak… - 2023 - muni.cz
BACKGROUND In a multinational, phase 3, head-to-head trial, ibrutinib, a Bruton's tyrosine
kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater …
kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater …
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
J Brown, B Eichhorst, P Hillmen, W Jurczak… - N. Engl. J. Med. - kups.ub.uni-koeln.de
BACKGROUND In a multinational, phase 3, head-to-head trial, ibrutinib, a Bruton's tyrosine
kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater …
kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater …
[引用][C] Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia
JR Brown, B Eichhorst, P Hillmen, W Jurczak… - New England Journal …, 2023 - ruj.uj.edu.pl
Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia Przejdź do
treści Pomoc A A A Zmień kontrast Zaloguj English polski Repozytorium …
treści Pomoc A A A Zmień kontrast Zaloguj English polski Repozytorium …
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
J Brown, B Eichhorst, P Hillmen, W Jurczak… - N. Engl. J. Med. - kups.ub.uni-koeln.de
BACKGROUND In a multinational, phase 3, head-to-head trial, ibrutinib, a Bruton's tyrosine
kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater …
kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater …